Skip to main content
SpringerLink
Log in

Nimotuzumab in the Management of Recurrent Endometrial Carcinoma: A Case Report

  • Case Report
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Ervik M et al. 2013. GLOBOCAN 2012. v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 20 March 2017.

  2. Gehrig Paola A, Bae-Jump Victoria L. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol. 2010;116(2):187–94.

    Article  PubMed  CAS  Google Scholar 

  3. Reddy BKM, Lokesh V, Vidyasagar MS, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50(5):498–505.

    Article  PubMed  CAS  Google Scholar 

  4. Kong L, et al. Radiation plus concurrent nimotuzumab versus cisplatin-based chemotherapy in locally advanced nasopharyngeal cancer: an interim analysis of a phase 3 randomized clinical trial. Int J Radiat Oncol Biol Phys. 2015;93(3):S129.

    Article  Google Scholar 

  5. Strumberg D, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investig New Drugs. 2012;30:1138–43.

    Article  CAS  Google Scholar 

  6. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther. 2012;13(8):600–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Authors would like to acknowledge Dr. Sameer Chaudhari for drafting and editing the manuscript.

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Netaji Subhash Chandra Bose Medical College and Hospital, Tilwara Road, Jabalpur, Madhya Pradesh, 482003, India

    Shyamji Rawat

Authors
  1. Shyamji Rawat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shyamji Rawat.

Ethics declarations

Conflict of interest

None.

Research involving Human Participants and/or Animals

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed Consent

The author haven’t suggested any personal information that may make the identity of the patient recognizable in any forms of description part, photograph or pedigree. The author have received the consent in writing form.

Additional information

Dr. Shyamji Rawat is the associate professor of the Department of Radiotherapy, Netaji Subhash Chandra Bose Medical College and Hospital, Jabalpur, Madhya Pradesh, India.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rawat, S. Nimotuzumab in the Management of Recurrent Endometrial Carcinoma: A Case Report. J Obstet Gynecol India 68, 417–419 (2018). https://doi.org/10.1007/s13224-017-1056-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13224-017-1056-6

Search

Navigation